Etanercept biosimilar (Shilpa Biologicals)

依那西普生物类似药（Shilpa Biologicals）

Report date: 2024/08/21 14:09:32

Base Information

Drug NameEtanercept biosimilar (Shilpa Biologicals)
Drug Alias NameSBDM-01
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionTumor necrosis factor β inhibitorsTumor necrosis factor α inhibitors
TargetsTumor necrosis factor βTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisPolyarticular Juvenile Idiopathic ArthritisArthritis, Rheumatoid +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesShilpa Biologicals Pvt Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShilpa Biologicals Pvt Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPolyarticular Juvenile Idiopathic ArthritisArthritis, Rheumatoid +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A